The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers...
Date First Received: August 2, 2006
Last Updated: February 6, 2008
Verified by: University of Pittsburgh, February 2008
Clinical Trial Phase: N/A | Start Date: August 2006
Overall Status: Recruiting
Estimated Enrollment: 25
Brief Summary
Official Title: “Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study
Detailed Clinical Trial Description
Migraine sufferers undergo vestibular tests to note abnormalities. There are 2 experimental visits in which migraine sufferers are given either the Rizatriptan or a fake pill and then are asked to rotate in a chair that is tilted. Motion sickness scores are taken throughout testing.
Outcome Measures for this Clinical Trial
Primary:
- Motion Sickness Scores Prospective No
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- History of Motion Sickness
- Currently suffering from migraines with at least 2 episodes during the previous 12 months
- Previous use and tolerance to triptans
Exclusion Criteria:
- Current tobacco user
- History of or current hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease
- Family history of early myocardial infarction (first-degree relative < 45 years old at time of event)
- Constant dizziness or constant vestibular symptoms
- History of ENT disease, e.g. Meniere's disease
- Current treatment with propranolol or medications that would preclude use of a triptan(e.g. ergotamine)
- Major vestibular abnormality found on screening
- Testing positive on over-the-counter pregnancy test
- Taken an MAO inhibitor within two weeks of testing
- Allergy or intolerance to gelatin
- Corrected visual acuity of > 20/40 O.U.
- Women who are pregnant or breastfeeding
Clinical Trials Locations, Contact Details, and Sponsors
Lead Sponsor: University of Pittsburgh
University of Pittsburgh
Pittsburgh Pennsylvania 15213 United States
Overall Clinical Trial Officials and Contacts
Joseph M Furman, MD, PhD Principal Investigator University of Pittsburgh
Overall Contact: Susan Strelinski (412) 647-8088 strelinskisb@upmc.edu
Additional Information
Information obtained from ClinicalTrials.gov on July 23, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00360282
Study ID Number: 0602009
ClinicalTrials.gov Identifier: NCT00360282
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
